stapokibart   Click here for help

GtoPdb Ligand ID: 13785

Synonyms: CM-310 | CM310
Approved drug Immunopharmacology Ligand
stapokibart is an approved drug
Compound class: Antibody
Comment: Stapokibart (CM310) is a humanized monoclonal antibody that targets interleukin-4 receptor α-subunit (IL-4Rα) [1]. It was designed for anti-inflammatory potential.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Stapokibart (CM310) is under clinical evaluation as a treament for a range of type 2 inflammatory diseases. The Chinese drug regulator (NMPA) approved stapokibart (Kangyueda®) in September 2024. It is indicated to treat moderate-to-severe atopic dermatitis [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05265923 A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis Phase 3 Interventional Keymed Biosciences Co.Ltd
NCT05908721 Study of CM310 in Patients With Allergic Rhinitis Phase 2 Interventional Keymed Biosciences Co.Ltd
NCT05908032 Study of CM310 in Subjects With Allergic Rhinitis Phase 3 Interventional Keymed Biosciences Co.Ltd
NCT05715320 Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2 Interventional Keymed Biosciences Co.Ltd